Immunohistochemical staining for beta-amyloid precursor protein (betaAPP) is a well-established marker of traumatic @entity21 in adults. Recent studies have used similar techniques to evaluate nonaccidental central @entity4215 (NAI) in @entity1 and young @entity1 . In this prospective study, we report the results of betaAPP immunohistochemistry on the brain and spinal cord in 28 pediatric cases of NAI. BetaAPP-immunoreactive axons were present in 27/28 cases. @entity21962 ( @entity21962 ) due to @entity4 and secondary vascular compromise was the most common pattern of betaAPP immunoreactivity and was detected in 22 of 28 cases. @entity130 was detected in 19/28 cases, although only eight of these cases showed brainstem staining, thus fulfilling the criteria for the diagnosis of diffuse traumatic @entity21 (dTAI). TAI and @entity21962 were both present in 16/28 cases. Isolated TAI and @entity21962 occurred in three and five cases, respectively. All @entity1 with isolated @entity21962 were <18 months of age. An additional finding highlighted by betaAPP immunostaining was a penumbra of @entity21 adjacent to focal lesions, such as lacerations. We conclude that betaAPP immunohistochemistry aids in documenting @entity130 in nonaccidental central @entity4215 in @entity1 and young @entity1 and that @entity21962 is a common finding.

Beta-amyloid precursor protein staining of nonaccidental central XXXX in pediatric autopsies.

@entity1 :: ('9606', 'Species') :: ['children', 'infants'] @entity4215 :: ('MESH:D020196', 'Disease') :: ['nervous system injury'] @entity4 :: ('MESH:D004487', 'Disease') :: ['brain swelling'] @entity21962 :: ('MESH:D020144', 'Disease') :: ['Vascular axonal injury', 'VAI'] @entity21 :: ('MESH:D001480', 'Disease') :: ['axonal injury'] @entity130 :: ('MESH:D014947', 'Disease') :: ['Traumatic axonal injury', 'trauma']
@entity4215 :: (MESH:D020196,Disease) :: ['nervous system injury']
